alefacept

Home
Ligands
alefacept

GtoPdb Ligand ID: 6787

Synonyms: Amevive® | BG 9273 | BG 9712 | BG-9273 | BG-9712 | Lfa3Tip

alefacept is an approved drug (FDA (2003))

Compound class: Peptide or derivative

Comment: This is a fusion protein of the CD2 ligand (CD58/LFA3, lymphocyte function associated antigen 3) linked to the Fc domain of IgG1. The construct is called LFA3TIP in [2].

No information available.

No information available.

Summary of Clinical Use
This drug was approved for the treatment of inflammation in moderate to severe psoriasis with plaque formation. Use of alefacept has since been discontinued in the US.

Summary of Clinical Use

This drug was approved for the treatment of inflammation in moderate to severe psoriasis with plaque formation. Use of alefacept has since been discontinued in the US.

Mechanism Of Action and Pharmacodynamic Effects
When alefacept binds to CD2 on the surface of T cells, it prevents the CD2/LFA3 interaction required to generate the co-stimulatory signal which would activate the T cells. This action inhibits the activation of CD4⁺ and CD8⁺ T cells resulting an immunosuppressive effect which results in reduced proliferation of keratinocytes, hyperproliferation of which cause psoriatic plaque formation [2].

Mechanism Of Action and Pharmacodynamic Effects

When alefacept binds to CD2 on the surface of T cells, it prevents the CD2/LFA3 interaction required to generate the co-stimulatory signal which would activate the T cells. This action inhibits the activation of CD4⁺ and CD8⁺ T cells resulting an immunosuppressive effect which results in reduced proliferation of keratinocytes, hyperproliferation of which cause psoriatic plaque formation [2].